SCHEMBL30061522

SCHEMBL30061522

CC(C)(C)OC(=O)N1C2CCCC1CN(c1ccc3c(c1)OCC(NC(=O)OCc1ccccc1)C3)C2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CTSL P07711 1/20 0.41
CTSB P07858 1/20 0.41
CTSK P43235 1/20 0.41
TMEM97 Q5BJF2 5/20 0.40
SIGMAR1 Q99720 5/20 0.40
HTR1A P08908 2/20 0.40
HRH2 P25021 2/20 0.40
HRH1 P35367 2/20 0.40
HRH3 Q9Y5N1 2/20 0.40
ADRA2C P18825 1/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
ACHE P22303 2/20 0.40
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM5 P08912 1/20 0.39
ADRA2A P08913 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20722630 1.00 KMT2A (0.44) KMT2AL3MBTL1CTSLCTSBCTSK
SCHEMBL20722437 0.98 CTSL (0.41) KMT2AL3MBTL1CTSLCTSBCTSK
SCHEMBL30060163 0.98 CTSL (0.41) KMT2AL3MBTL1CTSLCTSBCTSK
SCHEMBL20722775 0.90 CTSL (0.44) CTSLCTSBCTSKTMEM97SIGMAR1
SCHEMBL20722819 0.88 CTSL (0.45) KMT2ACTSLCTSBCTSKTMEM97
SCHEMBL22644950 0.85 LTB4R (0.40) KMT2AL3MBTL1GPR119LTB4RLTB4R2
SCHEMBL30059971 0.85 CA1 (0.49) KMT2AL3MBTL1CTSLCTSBCTSK
SCHEMBL20722755 0.85 CA1 (0.49) KMT2AL3MBTL1CTSLCTSBCTSK
SCHEMBL21685764 0.85 CTSL (0.48) KMT2AL3MBTL1CTSLCTSBCTSK
SCHEMBL24730159 0.84 KMT2A (0.39) KMT2AL3MBTL1CTSLCTSBCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162888-B2 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2024-12-10 US disclosed
CN-112867712-B Carboxamide as ubiquitin-specific protease inhibitor 瓦洛早期发现股份有限公司 2024-07-16 CN disclosed
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 KMT2A 339/4885L3MBTL1 1885/4885CTSL 400/4885
US-12162888-B2 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 KMT2A 339/4885L3MBTL1 1885/4885CTSL 400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.